Pub Date : 2023-04-01DOI: 10.4103/crst.crst_272_22
Mayakannan Krishnan, C. Ranjith
The use of high-energy charged particles in radiotherapy has evolved into an advanced cancer treatment. Even though proton beams and carbon ions are currently the popular particles used for radiotherapy in cancer, ions such as pions, helium, argon, and neon were previously used. To prepare this article, reviewed the literature relevant to the history, current status, and clinical outcomes of particle therapy for specific types of tumors by searching in PubMed and Google Scholar using specific search terms. This article reviews the history, current status, physics, and radiobiological advantages of particle therapy. Outcomes of particle therapy for sites such as the head-and-neck, central nervous system, lung, and prostate have been discussed. The physical and biological properties of particle therapy have been shown to be effective in reducing radiation-induced acute toxicities to a large extent as well as reducing the integral dose, i.e., the sum of dose delivered at every point in a patient's body, multiplied by the volume of tissue at each point and then added up over the entire treated volume. It is used to assess the potential risks associated with radiation therapy. The advantages of particle therapy over conventional photon therapy in terms of overall survival and local control rates have been described. Advances in image guidance and newer particle acceleration technologies have improved the efficiency of particle therapy treatment.
{"title":"A narrative review of particle therapy in cancer","authors":"Mayakannan Krishnan, C. Ranjith","doi":"10.4103/crst.crst_272_22","DOIUrl":"https://doi.org/10.4103/crst.crst_272_22","url":null,"abstract":"The use of high-energy charged particles in radiotherapy has evolved into an advanced cancer treatment. Even though proton beams and carbon ions are currently the popular particles used for radiotherapy in cancer, ions such as pions, helium, argon, and neon were previously used. To prepare this article, reviewed the literature relevant to the history, current status, and clinical outcomes of particle therapy for specific types of tumors by searching in PubMed and Google Scholar using specific search terms. This article reviews the history, current status, physics, and radiobiological advantages of particle therapy. Outcomes of particle therapy for sites such as the head-and-neck, central nervous system, lung, and prostate have been discussed. The physical and biological properties of particle therapy have been shown to be effective in reducing radiation-induced acute toxicities to a large extent as well as reducing the integral dose, i.e., the sum of dose delivered at every point in a patient's body, multiplied by the volume of tissue at each point and then added up over the entire treated volume. It is used to assess the potential risks associated with radiation therapy. The advantages of particle therapy over conventional photon therapy in terms of overall survival and local control rates have been described. Advances in image guidance and newer particle acceleration technologies have improved the efficiency of particle therapy treatment.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"137 1","pages":"248 - 260"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90636811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_144_23
Raju Vaishya, S. Kambhampati, K. Iyengar, A. Vaish
{"title":"ChatGPT in the current form is not ready for unaudited use in healthcare and scientific research","authors":"Raju Vaishya, S. Kambhampati, K. Iyengar, A. Vaish","doi":"10.4103/crst.crst_144_23","DOIUrl":"https://doi.org/10.4103/crst.crst_144_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"19 1","pages":"336 - 337"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81728910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_195_23
Vijeta Bajpai, A. Batra, Rahul Sarode
{"title":"Authors' reply to Sabu et al.","authors":"Vijeta Bajpai, A. Batra, Rahul Sarode","doi":"10.4103/crst.crst_195_23","DOIUrl":"https://doi.org/10.4103/crst.crst_195_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"72 1","pages":"326 - 326"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79106183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_157_23
Tejas S. Sathe, Madelyn A. Flitcroft, A. Kothari
{"title":"Democratizing scientific and healthcare communication with large language models","authors":"Tejas S. Sathe, Madelyn A. Flitcroft, A. Kothari","doi":"10.4103/crst.crst_157_23","DOIUrl":"https://doi.org/10.4103/crst.crst_157_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"33 1","pages":"333 - 334"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90441931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_166_23
Anupa John, V. Noronha, Ajay Singh, N. Nandini Menon, K. Prabhash
Epidermal growth factor receptor (EGFR) activating mutations are known oncogenic drivers in non-small-cell lung cancer (NSCLC), with 85% attributable to an exon 19 deletion or exon 21 L858R point substitution. The next most common is an exon 20 insertion mutation (Ex20Ins), which results in an altered active site that sterically interferes with tyrosine kinase inhibitor (TKI) binding, resulting in a poorer response rate to EGFR TKIs. Amivantamab (JNJ-61186372), a fully humanized EGFR- mesenchymal-epithelial transition receptor (MET) bispecific antibody has been approved for use in adults with locally advanced or metastatic NSCLC with EGFR Ex20Ins mutations, whose disease has progressed on or after platinum-based chemotherapy. To prepare this review, we searched various websites, including the European Medicines Agency Drug Manual, United States Food and Drug Administration, PubMed, Science Direct, and UpToDate using the search terms, “Amivantamab,” “NJ-61186372,” “amivantamab-vmjw,” and” “EGFRexon20ins.” We shortlisted 121 articles published between 2015 and 2023, of which 49 were included. This review discusses the clinical indications, adverse effects, safety, pharmacodynamics, pharmacokinetics, and the key research trials that investigated the use of amivantamab.
{"title":"Amivantamab: A narrative drug review","authors":"Anupa John, V. Noronha, Ajay Singh, N. Nandini Menon, K. Prabhash","doi":"10.4103/crst.crst_166_23","DOIUrl":"https://doi.org/10.4103/crst.crst_166_23","url":null,"abstract":"Epidermal growth factor receptor (EGFR) activating mutations are known oncogenic drivers in non-small-cell lung cancer (NSCLC), with 85% attributable to an exon 19 deletion or exon 21 L858R point substitution. The next most common is an exon 20 insertion mutation (Ex20Ins), which results in an altered active site that sterically interferes with tyrosine kinase inhibitor (TKI) binding, resulting in a poorer response rate to EGFR TKIs. Amivantamab (JNJ-61186372), a fully humanized EGFR- mesenchymal-epithelial transition receptor (MET) bispecific antibody has been approved for use in adults with locally advanced or metastatic NSCLC with EGFR Ex20Ins mutations, whose disease has progressed on or after platinum-based chemotherapy. To prepare this review, we searched various websites, including the European Medicines Agency Drug Manual, United States Food and Drug Administration, PubMed, Science Direct, and UpToDate using the search terms, “Amivantamab,” “NJ-61186372,” “amivantamab-vmjw,” and” “EGFRexon20ins.” We shortlisted 121 articles published between 2015 and 2023, of which 49 were included. This review discusses the clinical indications, adverse effects, safety, pharmacodynamics, pharmacokinetics, and the key research trials that investigated the use of amivantamab.","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"22 1","pages":"261 - 271"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80041556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-01DOI: 10.4103/crst.crst_113_23
Sunny Chi Lik Au
{"title":"Patient with cancer who found support and care from ChatGPT","authors":"Sunny Chi Lik Au","doi":"10.4103/crst.crst_113_23","DOIUrl":"https://doi.org/10.4103/crst.crst_113_23","url":null,"abstract":"","PeriodicalId":9427,"journal":{"name":"Cancer Research, Statistics, and Treatment","volume":"62 1","pages":"305 - 307"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89597559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：